2. Signaling Pathways
  3. GPCR/G Protein
  4. Angiotensin Receptor
  5. AT1 Receptor Isoform
  6. AT1 Receptor Antagonist

AT1 Receptor Antagonist

AT1 Receptor Antagonists (39):

Cat. No. Product Name Effect Purity
  • HY-17512
    Losartan
    		Antagonist 99.57%
    Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
  • HY-13955
    Telmisartan
    		Antagonist 99.79%
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-P11389
    (Sar1,Gly8)-Angiotensin II
    		Antagonist
    (Sar1,Gly8)-Angiotensin II is an AT1 angiotensin II receptor subtype selective antagonist (Ki: 52 nM for AT2 receptor in rat adrenal). (Sar1,Gly8)-Angiotensin II potently antagonizes dipsogenic responses to intracerebroventricularly administered Ang II.
  • HY-180401
    DMP 811
    		Antagonist
    DMP 811 is a potent, orally active and selective angiotensin II subtype receptor AT1 antagonist. DMP 811 exhibits selectivity for AT1 (IC50 = 6 nM) over AT2 (IC50 >10 μM). DMP 811 exhibits potent antihypertensive activity in rats and dogs. DMP 811 can be used for the research of hypertension.
  • HY-19253A
    KRH-594
    		Antagonist
    KRH-594 is an orally active angiotensin AT1 receptor antagonist. KRH-594 ameliorates the progression of diabetic nephropathy and hyperlipidaemia. KRH-594 inhibits cardiac hypertrophy.
  • HY-18204
    Valsartan
    		Antagonist 99.97%
    Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-17512A
    Losartan potassium
    		Antagonist 99.98%
    Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
  • HY-12403
    Talfirastide
    		Antagonist 99.91%
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
  • HY-17004
    Olmesartan
    		Antagonist 99.91%
    Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
  • HY-P0216
    A 779
    		Antagonist 99.55%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.
  • HY-12403A
    Talfirastide acetate
    		Antagonist 99.76%
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium.
  • HY-14914
    Azilsartan
    		Antagonist 99.68%
    Azilsartan (TAK-536) is an orally active, potent, selective and specific angiotensin II type 1 receptor (AT1) antagonist. Azilsartan induces ROS formation and apoptosis in HepG2 cells. Azilsartan shows neuroprotective and anticancer activity. Azilsartan can be used for hypertension and stroke research.
  • HY-12405
    CGP-42112
    		Antagonist 99.84%
    CGP-42112 (CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
  • HY-14736
    Azilsartan medoxomil
    		Antagonist 99.07%
    Azilsartan medoxomil (TAK 491), a prodrug form of Azilsartan (HY-14914), is an orally active angiotensin II receptor type 1 antagonist. Azilsartan medoxomil can be used for the study of essential hypertension.
  • HY-B0780
    Fimasartan
    		Antagonist 99.60%
    Fimasartan (BRA-657) is an orally effective angiotensin receptor AT1 non-peptide antagonist. Fimasartan has antihypertensive effects. Fimasartan improves neuroinflammation and brain injury mediated by NLRP3 inflammatome after intracerebral hemorrhage, and has neuroprotective effect. Fimasartan inhibits the expression of inducible nitric oxide synthase through the inactivation of NF-κB and activator protein-1.
  • HY-A0250
    Tasosartan
    		Antagonist 99.32%
    Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
  • HY-19732
    BIBS 39
    		Antagonist 99.70%
    BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.
  • HY-102093
    ZD 7155hydrochloride
    		Antagonist 99.88%
    ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.
  • HY-18204S
    Valsartan-d9
    		Antagonist 99.33%
    Valsartan-d9 is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
  • HY-114412A
    TD-0212 TFA
    		Antagonist 98.44%
    TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP.